Edwards Lifesciences Corp
For the period ended Dec 31, 2023. Filed Feb 12, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Feb 12, 2024
EW$104.01-0.7%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Comprehensive Income
| Years Ended December 31, | |||
|---|---|---|---|
| 2023 | 2022 | 2021 | |
| Net income | $1,399.4 | $1,521.9 | $1,503.1 |
| Other comprehensive income (loss), net of tax (Note 16): | |||
| Foreign currency translation adjustments | 4.3 | (46.3) | (50.1) |
| Unrealized (loss) gain on hedges | (23.1) | (5.9) | 57.4 |
| Unrealized pension (costs) credits | (9.9) | 13.7 | 11.6 |
| Unrealized gain (loss) on available-for-sale investments | 40.8 | (58.7) | (15.5) |
| Other comprehensive income (loss), net of tax | 12.1 | (97.2) | 3.4 |
| Comprehensive income | 1,411.5 | 1,424.7 | 1,506.5 |
| Comprehensive loss attributable to noncontrolling interest | (3.0) | — | — |
| Comprehensive income attributable to Edwards Lifesciences Corporation | $1,414.5 | $1,424.7 | $1,506.5 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.